Rozan M. Radwan^1,2, Safaa Yehia Eid^3*
1Departmentof Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 24381, Saudi Arabia
²Department of Medical Training, Al-Noor Specialist Hospital, Makkah, Saudi Arabia
³Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 24381, Saudi Arabia
Volume: 10 | Issue: 2 | Pages: 195-203 | December 2024-|-https://doi.org/10.54940/ms45778777-|-PDF
Received:-23/10/2024-|-Received:-10/11/2024-|-Accepted:-2/12/2024
*Corresponding Author: syeid@uqu.edu.sa

Abstract
Background:-Since COVID-19 was declared a pandemic by the World Health Organization (WHO), there have been many changes in treatment protocols. With the rise of COVID-19 cases globally and the absence of any approved medicine for the treatment of (COVID-19), many drugs have been experimentally administered to patients, ignoring possible side effects. Some of these drugs have a background of potential cardiotoxicity that should be evaluated.
Methods:-A retrospective study will be conducted on patients’ admissions to (ICU) or (CCU) in Al-Noor Hospital in the Kingdom of Saudi Arabia to treat COVID-19. The effect of the drugs used in the management of COVID-19 on the cardiac parameters of patients will be evaluated and compared with COVID-19 medications that cause cardiotoxicity in patients.
Results:-The patients were having Symptoms included arrhythmia (56.3%), murmur (43.0%), QT prolongation (54.3%), chest pain (54.3%), shortness of breath (55.0%), heart palpitation (45.7%), fluid retention (47.0%) and myocarditis (51.7%). ICU admission diagnoses in most patients were COVID exacerbation (51.7%) and pneumonia (38.4%). Different classes of antibiotics and antivirals were administered to the patients, and a high risk of cardiac manifestations was observed in patients using Ribavirin which was used in 51 patients (33.8%).
Conclusion:-The study showed that cardiotoxic symptoms appear among patients using anti-COVID medications, especially Ribavirin. Therefore, there is a need to limit the use of medicines for COVID-19, which causes cardiotoxicity and change the protocol used in Saudi Arabia.

Keywords
Cardiotoxicity, COVID-19 Patients, Ribavirin, Arrhythmia, Murmur.

How to Cite
Radwan, R. M., & Eid, S. Y. (2024). Cardiotoxicity of Drugs Used in the Management of the COVID-19 Patients: Single-Center Retrospective Study,-Journal of Umm Al-Qura University for Medical Sciences, 10(2), 195-203.-https://doi.org/10.54940/ms45778777

License
1658-4740/© 2024-by the Authors. Published by-J. Umm Al-Qura Univ. Med. Sci.-This is an open-access article distributed under the terms and conditions of the-https://creativecommons.org/licenses/by-nc/4.0/-